How much profit has Regeneron Pharmaceuticals made this year?
Regeneron Pharmaceuticals has made 5.02 B USD this year.
In 2024, Regeneron Pharmaceuticals's profit amounted to 5.02 B USD, a 27.03% increase from the 3.95 B USD profit recorded in the previous year.
YEAR | NET INCOME (undefined USD) |
---|---|
2029e | 7.08 |
2028e | 6.55 |
2027e | 6.09 |
2026e | 5.79 |
2025e | 5.3 |
2024e | 5.02 |
2023 | 3.95 |
2022 | 4.34 |
2021 | 8.08 |
2020 | 3.51 |
2019 | 2.12 |
2018 | 2.44 |
2017 | 1.2 |
2016 | 0.9 |
2015 | 0.64 |
2014 | 0.34 |
2013 | 0.42 |
2012 | 0.75 |
2011 | -0.22 |
2010 | -0.1 |
2009 | -0.07 |
2008 | -0.08 |
2007 | -0.11 |
2006 | -0.1 |
2005 | -0.1 |
2004 | 0.04 |
In the annual report of the Regeneron Pharmaceuticals share (US75886F1075, 881535, REGN), it breaks down its revenues into 1 segments: 1. Medicines. The Regeneron Pharmaceuticals stock (WKN: 881535, ISIN: US75886F1075, Ticker Symbol: REGN) is a leading investment for investors interested in participating in the Health Care sector.
The profit margins of Regeneron Pharmaceuticals represent the net income earned after deducting all operational expenses, costs, and taxes from the revenue. This figure is a clear indicator of Regeneron Pharmaceuticals's financial health, operational efficiency, and profitability. Higher profit margins signify better cost management and income generation capabilities.
Evaluating Regeneron Pharmaceuticals's profit on a yearly basis can offer significant insights into its financial growth, stability, and trends. A consistent increase in profit suggests improved operational efficiency, cost management, or increased revenue, while a decrease may indicate rising costs, declining sales, or operational challenges.
Regeneron Pharmaceuticals's profit figures are critical for investors who are aiming to understand the company's financial standing and future growth prospects. Increased profits often lead to higher stock valuations, boosting investor confidence and attracting more investments.
When Regeneron Pharmaceuticals’s profit increases, it often indicates enhanced operational efficiency or increased sales. In contrast, a decline in profit can signal operational inefficiencies, increased costs, or competitive pressures, necessitating strategic interventions to boost profitability.
Regeneron Pharmaceuticals has made 5.02 B USD this year.
The profit has increased by 27.03% compared to last year increased
An increase in earnings is usually seen as a positive indicator for shareholders as it means that the company is generating profits.
Regeneron Pharmaceuticals publishes its earnings in the form of quarterly or annual reports.
The quarterly or annual reports contain information about sales and profit, cash flow, balance sheet, and other fundamentals.
The profits of Regeneron Pharmaceuticals are an important indicator of the financial health of the company and can help investors decide whether they want to invest in the company or not.
You can learn more about the earnings of Regeneron Pharmaceuticals by reviewing the quarterly or annual reports or following the company presentations.
Over the past 12 months, Regeneron Pharmaceuticals paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Regeneron Pharmaceuticals is expected to pay a dividend of 0 USD.
The current dividend yield of Regeneron Pharmaceuticals is .
Regeneron Pharmaceuticals pays a quarterly dividend. This is distributed in the months of .
Regeneron Pharmaceuticals paid dividends every year for the past 0 years.
For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.
Regeneron Pharmaceuticals is assigned to the 'Health' sector.
To receive the latest dividend of Regeneron Pharmaceuticals from 4/19/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 4/19/2024.
The last dividend was paid out on 4/19/2024.
In the year 2023, Regeneron Pharmaceuticals distributed 0 USD as dividends.
The dividends of Regeneron Pharmaceuticals are distributed in USD.
The Regeneron Pharmaceuticals stock can be added to a savings plan with the following providers: Trade Republic, ING, Scalable Capital and Consorsbank
Our stock analysis for Regeneron Pharmaceuticals Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Regeneron Pharmaceuticals Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.